Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab.

A high P1NP value at Month 3 predicted large increases in both L-BMD and TH-BMD at Month 12 in postmenopausal osteoporosis patients treated with romosozumab.